Lung cancer
Improving Performance Status (General condition) in Advanced Lung cancer with chemotherapy and Immunotherapy
Who can joinAdults
Age18–65 years
Kind of studyPhase 2: does it work?
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHINew Delhi, DelhiDirections ↗
Registry summary (technical)
An open label phase-2 randomized-clinical-trial to evaluate the efficacy and safety of low-dose nivolumab and low-dose chemotherapy in patients of advanced NSCLC with poor PS - ImPACt-I
Sponsor: Indian Council of Medical Research
CTRI/2025/03/082809 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 5 Oct 2026 · read by us 5 Nov 2026